Table 1.

Responses to the pre-meeting survey

	Responses (%)
	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Unmet needs in RRMS	23	63	10	3	0
There is still an unmet medical need in the treatment of RRMS	40	60	0	0	0
Some of the most effective medications that suppress disease activity also have severe safety and tolerability issues	10	90	0	0	0
Complexity and side effect profile of current treatment options result in poor treatment adherence	20	40	30	10	0
Early treatment of RRMS	65	27.5	7.5	0	0
The regenerative potential of the brain is limited and becomes less effective with age	50	30	20	0	0
Early treatment in RRMS is important for better long-term disease outcomes	80	20	0	0	0
Earlier intervention with highly effective DMTs results in better long-term disease control	60	40	0	0	0
“Time is Brain”: MS damages the whole brain, and damage begins from the start of the disease	70	20	10	0	0
Selective B cell targeting	25	65	10	0	0
B cells are an appropriate target for a long-term treatment strategy in patients with RRMS	30	60	10	0	0
Selective targeting of B cells is a long-term treatment strategy	30	60	10	0	0
With B cell therapy, low rates of infection in clinical trials support the hypothesis of preserved immune surveillance	10	80	10	0	0
B cells are drivers of MS pathogenesis	30	60	10	0	0
I involve my patients’ preference when it comes to making treatment decisions	60	40	0	0	0

Text in bold indicates main survey topics and the mean overall levels of agreement for each topic

DMT disease-modifying treatment, MS multiple sclerosis, RRMS relapsing–remitting MS